The FDA-approved BRAF/MEK inhibitor combination of dabrafenib and trametinib has revolutionized treatment of BRAFV600E mutation positive anaplastic thyroid cancer. Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.